Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm pediatric evolocumab study in familial hypercholesterolemia
2015-002276-25Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of evolocumab in familial hypercholesterolemia (FH), heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH) and 1 more (2 cohorts), sponsored by Amgen. Primary endpoint: Incidence of treatment-emergent adverse events. Started Apr 2016; status: completed.
02
Drugs
evolocumab
03
Conditions
familial hypercholesterolemia (FH)heterozygous familial hypercholesterolemia (HeFH)homozygous familial hypercholesterolemia (HoFH)hypercholesterolemia
Beyond the preview
Go deeper on 2015-002276-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002276-25.